These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 16434248

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL.
    J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
    [Abstract] [Full Text] [Related]

  • 3. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE.
    J Clin Oncol; 2006 Oct 20; 24(30):4895-900. PubMed ID: 17001071
    [Abstract] [Full Text] [Related]

  • 4. Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series.
    Montella L, Addeo R, Palmieri G, Caraglia M, Cennamo G, Vincenzi B, Guarrasi R, Mamone R, Faiola V, Frega N, Capasso E, Maiorino L, Leopardo D, Pizza C, Montesarchio V, Del Prete S.
    Cancer Chemother Pharmacol; 2010 May 20; 65(6):1137-43. PubMed ID: 19760218
    [Abstract] [Full Text] [Related]

  • 5. [The efficacy of therapy using 89Sr-strontium chloride in 200 patients with bone metastases of a prostatic cancer].
    Haesner M, Buchali K, Pink V, Lips H.
    Nuklearmedizin; 1992 Mar 20; 31(2):48-52. PubMed ID: 1373485
    [Abstract] [Full Text] [Related]

  • 6. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein M, Coleman RE, Reitsma DJ, Seaman JJ, Chen BL, Ambros Y.
    Cancer J; 2001 Mar 20; 7(5):377-87. PubMed ID: 11693896
    [Abstract] [Full Text] [Related]

  • 7. [Strontium-89: a desirable therapeutic for bone metastases of prostate cancer].
    Ma YB, Yan WL, Dai JC, Xu F, Yuan Q, Shi HH.
    Zhonghua Nan Ke Xue; 2008 Sep 20; 14(9):819-22. PubMed ID: 18998467
    [Abstract] [Full Text] [Related]

  • 8. Bone pain palliation with 85Sr therapy.
    Giammarile F, Mognetti T, Blondet C, Desuzinges C, Chauvot P.
    J Nucl Med; 1999 Apr 20; 40(4):585-90. PubMed ID: 10210217
    [Abstract] [Full Text] [Related]

  • 9. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
    Leto G, Badalamenti G, Arcara C, Crescimanno M, Flandina C, Tumminello FM, Incorvaia L, Gebbia N, Fulfaro F.
    Anticancer Res; 2006 Apr 20; 26(1A):23-6. PubMed ID: 16475674
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Apr 20; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 11. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr 20; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 12. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
    Berenson JR, Vescio RA, Rosen LS, VonTeichert JM, Woo M, Swift R, Savage A, Givant E, Hupkes M, Harvey H, Lipton A.
    Clin Cancer Res; 2001 Mar 20; 7(3):478-85. PubMed ID: 11297237
    [Abstract] [Full Text] [Related]

  • 13. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
    Papatheofanis FJ.
    J Nucl Med; 1997 Aug 20; 38(8):1175-9. PubMed ID: 9255144
    [Abstract] [Full Text] [Related]

  • 14. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
    Nair N.
    J Nucl Med; 1999 Feb 20; 40(2):256-61. PubMed ID: 10025832
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S.
    J Clin Oncol; 2005 May 20; 23(15):3314-21. PubMed ID: 15738536
    [Abstract] [Full Text] [Related]

  • 16. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA.
    Oncologist; 2004 May 20; 9(6):687-95. PubMed ID: 15561812
    [Abstract] [Full Text] [Related]

  • 17. The management of painful bone metastases with biphosphonates and palliative radiotherapy: a retrospective evaluation of 372 cases.
    Niang U, Kamer S, Ozsaran Z, Haydaroglu A, Kilciksiz S.
    J BUON; 2009 May 20; 14(2):245-9. PubMed ID: 19650174
    [Abstract] [Full Text] [Related]

  • 18. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG, Preston DF, Schiefelbein M, Baxter KG.
    JAMA; 1995 Aug 02; 274(5):420-4. PubMed ID: 7542352
    [Abstract] [Full Text] [Related]

  • 19. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
    Papatheofanis FJ.
    J Nucl Med; 2000 Jun 02; 41(6):1021-4. PubMed ID: 10855628
    [Abstract] [Full Text] [Related]

  • 20. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol; 2007 Mar 01; 25(7):820-8. PubMed ID: 17159195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.